Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Leases: 2019-2022

Historic Capital Leases for Beam Therapeutics (BEAM) over the last 4 years, with Dec 2022 value amounting to $1.2 million.

  • Beam Therapeutics' Capital Leases fell 78.10% to $304,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $304,000, marking a year-over-year decrease of 78.10%. This contributed to the annual value of $1.2 million for FY2022, which is 61.62% down from last year.
  • Per Beam Therapeutics' latest filing, its Capital Leases stood at $1.2 million for FY2022, which was down 61.62% from $3.0 million recorded in FY2021.
  • Beam Therapeutics' Capital Leases' 5-year high stood at $5.3 million during FY2020, with a 5-year trough of $1.2 million in FY2022.
  • For the 3-year period, Beam Therapeutics' Capital Leases averaged around $3.2 million, with its median value being $3.0 million (2021).
  • Its Capital Leases has fluctuated over the past 5 years, first increased by 20.02% in 2020, then tumbled by 61.62% in 2022.
  • Over the past 4 years, Beam Therapeutics' Capital Leases (Yearly) stood at $4.4 million in 2019, then climbed by 20.02% to $5.3 million in 2020, then crashed by 43.20% to $3.0 million in 2021, then crashed by 61.62% to $1.2 million in 2022.